Arvinas, Inc. (ARVN)

NMS – Real vaqt narxi. Valyuta: USD

9.57

-0.09 (-0.93%)

Yopilishda: May 12, 2026, 4:00 PM EDT

12.05.2026

Arvinas Q1 Earnings Call Highlights

Arvinas NASDAQ: ARVN said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline focused on targeted protein degradation.

12.05.2026

Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates

Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to earnings of $1.14 per share a year ago.

12.05.2026

Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug

Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently approved breast cancer drug, marking Rigel's fourth ‌commercial product on the market.

12.05.2026

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

– First-ever FDA approved PROTAC supports the further development and potential of Arvinas' pipeline – – Announced FDA Approval of VEPPANU ™ (vepdegestrant) for the treatment of ESR1m, ER+/HER2- advanced breast cancer – – Announced selection of Rigel Pharmaceuticals for the exclusive global rights to VEPPANU – – Presented ARV-102 (LRRK2 degrader) Phase 1 clinical data in patients with Parkinson's disease demonstrating reduction in endolysosomal and neuroinflammatory biomarkers implicated in Parkinson's disease and progressive supranuclear palsy – – Presented ARV-6723 (HPK1 degrader) preclinical data at the American Associated of Cancer Research Annual meeting demonstrating the potential to overcome immune checkpoint inhibitor resistance in solid tumors – – Initiated dosing with ARV-027 (polyQ-AR degrader) in Phase 1 healthy volunteer trial with single-ascending dose data anticipated in 2H26 – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn.

12.05.2026

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

– Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, regulatory, and commercial milestones and tiered royalites on net sales – NEW HAVEN, Conn., May 12, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, and Pfizer Inc. (NYSE: PFE) have entered into a license agreement with Rigel Pharmaceuticals, Inc., a commercial stage biotechnology company focused on hematologic disorders and cancer, for the exclusive global development, manufacturing, and commercialization rights for VEPPANU™ (vepdegestrant).

05.05.2026

Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026

NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, May 12, 2026 at 8:00 a.m.

01.05.2026

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

– VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader – – Approval received in advance of FDA-assigned PDUFA date of June 5, 2026; Arvinas and Pfizer remain on track to announce selection of a third party – – VEPPANU offers a new therapeutic option in ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, where treatment resistance remains a major clinical challenge – NEW HAVEN, Conn., May 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today with its partner Pfizer Inc. (NYSE: PFE), announced that the U.S. Food and Drug Administration (FDA) has granted approval for VEPPANU (vepdegestrant) for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.

Videolar

No Data

There is no data to display

Press-relizlar

12.05.2026

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

12.05.2026

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

01.05.2026

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

18.03.2026

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days

– ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson's disease and progressive supranuclear palsy –

Arvinas, Inc. (ARVN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Arvinas, Inc. (ARVN)

Arvinas Q1 Earnings Call Highlights

Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates

Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Videolar

No Data

Press-relizlar

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days

Arvinas Q1 Earnings Call Highlights

Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates

Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Videolar

No Data

Press-relizlar

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days

Search stocks

Arvinas, Inc. (ARVN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Arvinas, Inc. (ARVN)

Arvinas Q1 Earnings Call Highlights

Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates

Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Videolar

No Data

Press-relizlar

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days

Arvinas Q1 Earnings Call Highlights

Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates

Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Videolar

No Data

Press-relizlar

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days